Amyris Inc (AMRS) 3.62 $AMRS
First International Commercial Flight Completed With Newly Approved Amyris-Total Aviation Biofuel
GlobeNewswire - Thu Jul 31, 12:52PM CDT
Yesterday, Amyris (Nasdaq:AMRS), an industrial bioscience company, partnered with Brazilian airline, GOL, to fly the industry's first commercial flight with farnesane, the recently approved renewable jet fuel. The first flight, GOL flight 7725, departed from Orlando, Florida on July 30, 2014 at 5:15 PM ET and traveled to Sao Paulo, Brazil.
Global Synthetic Biology Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4xp9d8/global_synthetic) has announced the addition of the "Global Synthetic Biology Market 2014-2018" report to their offering. The term synthetic biology covers the designing and engineering of completely new biological parts, devices, and organisms as well as the redesigning of natural biological systems that provide improved and desirable functions. It is considered to be a form of extreme genetic engineering because it not only alters existing metabolic pathways, but also creates new ones. The engineered biological systems can be used to manipulate chemicals, fabricate materials and structures, produce energy, provide GM food, improve the efficiency of drugs and vaccines, and maintain a sustainable environment. The analysts forecast the Global Synthetic Biology market will grow at a CAGR of 33.8 percent over the period 2013-2018. The Global Synthetic Biology market can be categorized on the basis of technology into four segments: Genome Engineering. DNA Sequencing, Bioinformatics, and Biological Components and Integrated Systems. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Technology 08. Market Segmentation by Product 09. Market Segmentation by Applications 10. Geographical Segmentation 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis 20. Other Reports in this Series Companies Mentioned: - Amyris Inc. - E. I. du Pont de Nemours and Co. - Thermo Fisher Scientific Inc. - Synthetic Genomics Inc. - Algenol Biofuels Inc. - ATG:biosynthetics GmbH - Bayer AG - Bioneer Corp. - Biosearch Technologies Inc. - Bristol-Myers Squibb Co. - CBC Comprehensive Biomarker Center GmbH - Cobalt Technologies - Evolva Holdings SA - Exxon Mobil Corp. - GeneWorks Pty Ltd. - Genomatica Inc. - Gevo Inc. - Ginkgo Bioworks - Green Biologics Ltd. - New England Biolabs Inc. - OriGene Technologies Inc. - REG Life Sciences LLC - Royal DSM - Synthorx Inc. For more information visit http://www.researchandmarkets.com/research/4x..._synthetic
Commit To Purchase Amyris At $2.50, Earn 15.3% Annualized Using Options
StockOptionsChannel.com - Fri Jul 25, 10:29AM CDT
Investors eyeing a purchase of Amyris, Inc. shares, but cautious about paying the going market price of $3.63/share, might benefit from considering selling puts among the alternative strategies at their disposal.
4 Cash-Strapped Companies on Life Support - Investment Ideas
Todd Bunton - ZACKS - Thu Jul 24, 5:15PM CDT
4 Cash-Strapped Companies on Life Support - Investment Ideas
Amyris to Announce Second Quarter Financial Results on Thursday, August 7, 2014
GlobeNewswire - Thu Jul 17, 7:17AM CDT
Amyris, Inc. (Nasdaq:AMRS) will report financial results for the second quarter ended June 30, 2014 after market close on Thursday, August 7, 2014.
Brazilian Airline GOL to Make First International Commercial Flights With Newly Approved Amyris-Total Aviation Biofuel
GlobeNewswire - Wed Jul 09, 7:00AM CDT
Amyris (Nasdaq:AMRS) has partnered with Brazilian airline GOL (NYSE:GOL) to begin the first commercial route with farnesane, the recently approved renewable jet fuel.
Should Amyris Investors Fear Intrexon's Farnesene?
Maxx Chatsko, The Motley Fool - Motley Fool - Mon Jul 07, 1:09PM CDT
When a company commercializes a building-block molecule with dozens, if not hundreds, of potential commercial uses, competition is bound to arrive sooner or later. When it comes to farnesene production, that competition may show up sooner than ...
What's the Value of Amyris' Molecule Development Strategy?
Maxx Chatsko, The Motley Fool - Motley Fool - Wed Jun 18, 11:50AM CDT
Artemisinin-based combination therapies are some of the most important weapons wielded by the developing world against malaria, which claims over 620,000 lives each year. While artemisinin is effective, its supply and cost is greatly affected by...
2014 Report on the International Synthetic Biology (Synthetic DNA, Synthetic Genes, Synthetic Cells, XNA, Chassis Organisms, DNA Synthesis, Oligonucleotide Synthesis) Market - Trends and Forecast to 2019
M2 - Wed Jun 18, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9bcz55/synthetic_biology) has announced the addition of the "2014 Report on the International Synthetic Biology (Synthetic DNA, Synthetic Genes, Synthetic Cells, XNA, Chassis Organisms, DNA Synthesis, Oligonucleotide Synthesis) Market - Trends and Forecast to 2019" report to their offering. Synthetic biology defined as the synthesis of artificial or natural components in order to form new artificial living system by re-molding existing biological elements. It aims to attain new preferred functions of artificially modified organisms intended for high yield production of biological systems. Synthetic biology plays an important role in the field of life sciences by developing cheap synthesis procedures. Increasing scientific research coupled with introduction of advanced technologies in synthetic biology will drive the growth of this market. The market for synthetic biology is segmented as: by products, by technologies and by applications. Product segment includes core products and enabling products. Core product segment comprises synthetic DNA, synthetic genes, synthetic cells, XNA and chassis organisms. While enabling products are segmented into DNA and oligonucleotide synthesis products. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Synthetic Biology Market, by Products Chapter 5 Global Synthetic Biology Market, by Technologies Chapter 6 Global Synthetic Biology Market, by Applications Chapter 7 Global Synthetic Biology Market, by Geography Chapter 8 Competitive Landscape Chapter 9 Recommendations Chapter 10 Company Profiles Companies Mentioned: - Agrivida, Inc. - Amyris, Inc. - Algenol Biofuels, Inc. - ATG:biosynthetics GmbH - Bayer AG - Bristol-Myers Squibb - BIONEER CORPORATION - Biosearch Technologies, Inc. - CBC Comprehensive Biomarker Center GmbH - Cobalt Technologies - DuPont, Inc. - Evolva SA - Exxon Mobil Corporation - Ginkgo Bioworks - GeneWorks Pty Ltd. - Genomatica, Inc. - GeneScript Corporation - Gevo, Inc. - Green Biologics Limited - New England Biolabs, Inc. - OriGene Technologies, Inc. - REG Life Sciences, LLC - Royal DSM - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/9b...ic_biology
Amyris Up 5.2%, Shares Break Through Resistance (AMRS)
Comtex SmarTrend(R) - Tue Jun 17, 11:39AM CDT
Amyris (NASDAQ:AMRS) is one of today's best performing low-priced stocks, up 5.2% to $3.85 on 1.2x average daily volume. Thus far today, Amyris has traded 326,000 shares, vs. average volume of 269,000 shares per day. The stock has outperformed the Dow (5.2% to the Dow's 0.1%) and outperformed the S&P 500 (5.2% to the S&P's 0.1%) during today's trading.
Total and Amyris Renewable Jet Fuel Ready for Use in Commercial Aviation
GlobeNewswire - Mon Jun 16, 6:55AM CDT
With the newly revised ASTM standard for jet fuel, Amyris (Nasdaq:AMRS) and Total (CAC:TOTF.PA) today begin to prepare to market a drop-in jet fuel that contains up to 10% blends of renewable farnesane.
A Warning for Biofuel Investors
Shamus Funk, The Motley Fool - Motley Fool - Thu Jun 12, 9:57AM CDT
It's hard to believe a company producing and selling shark liver oil and low-friction tire rubber could be telling a story that we've already heard before, but Amyris ' tale is one not unseen in the bio-product industry. Like a poorly written...
Takasago and Amyris to Begin Commercialization of Novel Fragrance Products
GlobeNewswire - Mon Jun 09, 6:12AM CDT
Takasago (TYO:4914), a global leader in the creation of flavors and fragrances for consumer products, and Amyris (Nasdaq:AMRS), a leading renewable products company, today announced the start of the next phase of their relationship to commercialize farnesene-derived fragrance molecules. Having successfully completed feasibility testing, Takasago agreed to move forward with commercialization, starting with a first purchase for scale-up this quarter.
The Good, the Bad, and the Ugly From Amyris' Financing Deal
Maxx Chatsko, The Motley Fool - Motley Fool - Wed May 28, 3:39PM CDT
Here's a list of words that were not uttered during the first-quarter conference call of synthetic biology leader Amyris on May 8: "Financing" "Convertible debt notes" "$90 million" Although it wasn't discussed on the call, the company...
Why Amyris Inc's Shares Jumped Today
Travis Hoium, The Motley Fool - Motley Fool - Fri May 23, 4:55PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Amyris Inc jumped 12% today after...
Amyris Prices $75 Million Convertible Senior Notes Due 2019
GlobeNewswire - Fri May 23, 6:00AM CDT
Amyris, Inc. (Nasdaq:AMRS) today announced that it has priced $75 million aggregate principal amount of 6.50% Convertible Senior Notes due 2019 (the "notes"
. The notes will be sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Amyris also granted the initial purchaser of the notes an option to purchase up to an additional $15 million aggregate principal amount of the notes. The sale is expected to close on May 29, 2014, subject to customary closing conditions.
Why Amyris, Total SA, and The Boeing Company Are Excited About Renewable Jet Fuel
Maxx Chatsko, The Motley Fool - Motley Fool - Thu May 22, 8:42AM CDT
Boeing 777 aircraft (and more) around the world could soon be powered in part by renewable fuels. Source: United Airlines / Wikimedia Commons . The global aviation industry accounts for roughly 2% of all greenhouse gas emissions. On a per-passenger...
Amyris to Offer $75 Million Convertible Senior Notes Due 2019
GlobeNewswire - Thu May 22, 6:37AM CDT
Amyris, Inc. (Nasdaq:AMRS), a leading renewable chemicals and fuels company, today announced that it proposes to offer $75 million aggregate principal amount of Convertible Senior Notes due 2019 (the "notes" , subject to market conditions and other factors. The notes are to be offered and sold in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Amyris also intends to grant to the initial purchaser of the notes an option to purchase up to an additional $15 million aggregate principal amount of notes.
4 Stocks Under $10 Making Big Moves
at The Street - Wed Apr 02, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
First International Commercial Flight Completed With Newly Approved Amyris-Total Aviation Biofuel
GlobeNewswire - Thu Jul 31, 12:52PM CDT
Yesterday, Amyris (Nasdaq:AMRS), an industrial bioscience company, partnered with Brazilian airline, GOL, to fly the industry's first commercial flight with farnesane, the recently approved renewable jet fuel. The first flight, GOL flight 7725, departed from Orlando, Florida on July 30, 2014 at 5:15 PM ET and traveled to Sao Paulo, Brazil.
Global Synthetic Biology Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4xp9d8/global_synthetic) has announced the addition of the "Global Synthetic Biology Market 2014-2018" report to their offering. The term synthetic biology covers the designing and engineering of completely new biological parts, devices, and organisms as well as the redesigning of natural biological systems that provide improved and desirable functions. It is considered to be a form of extreme genetic engineering because it not only alters existing metabolic pathways, but also creates new ones. The engineered biological systems can be used to manipulate chemicals, fabricate materials and structures, produce energy, provide GM food, improve the efficiency of drugs and vaccines, and maintain a sustainable environment. The analysts forecast the Global Synthetic Biology market will grow at a CAGR of 33.8 percent over the period 2013-2018. The Global Synthetic Biology market can be categorized on the basis of technology into four segments: Genome Engineering. DNA Sequencing, Bioinformatics, and Biological Components and Integrated Systems. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Technology 08. Market Segmentation by Product 09. Market Segmentation by Applications 10. Geographical Segmentation 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis 20. Other Reports in this Series Companies Mentioned: - Amyris Inc. - E. I. du Pont de Nemours and Co. - Thermo Fisher Scientific Inc. - Synthetic Genomics Inc. - Algenol Biofuels Inc. - ATG:biosynthetics GmbH - Bayer AG - Bioneer Corp. - Biosearch Technologies Inc. - Bristol-Myers Squibb Co. - CBC Comprehensive Biomarker Center GmbH - Cobalt Technologies - Evolva Holdings SA - Exxon Mobil Corp. - GeneWorks Pty Ltd. - Genomatica Inc. - Gevo Inc. - Ginkgo Bioworks - Green Biologics Ltd. - New England Biolabs Inc. - OriGene Technologies Inc. - REG Life Sciences LLC - Royal DSM - Synthorx Inc. For more information visit http://www.researchandmarkets.com/research/4x..._synthetic
Commit To Purchase Amyris At $2.50, Earn 15.3% Annualized Using Options
StockOptionsChannel.com - Fri Jul 25, 10:29AM CDT
Investors eyeing a purchase of Amyris, Inc. shares, but cautious about paying the going market price of $3.63/share, might benefit from considering selling puts among the alternative strategies at their disposal.
4 Cash-Strapped Companies on Life Support - Investment Ideas
Todd Bunton - ZACKS - Thu Jul 24, 5:15PM CDT
4 Cash-Strapped Companies on Life Support - Investment Ideas
Amyris to Announce Second Quarter Financial Results on Thursday, August 7, 2014
GlobeNewswire - Thu Jul 17, 7:17AM CDT
Amyris, Inc. (Nasdaq:AMRS) will report financial results for the second quarter ended June 30, 2014 after market close on Thursday, August 7, 2014.
Brazilian Airline GOL to Make First International Commercial Flights With Newly Approved Amyris-Total Aviation Biofuel
GlobeNewswire - Wed Jul 09, 7:00AM CDT
Amyris (Nasdaq:AMRS) has partnered with Brazilian airline GOL (NYSE:GOL) to begin the first commercial route with farnesane, the recently approved renewable jet fuel.
Should Amyris Investors Fear Intrexon's Farnesene?
Maxx Chatsko, The Motley Fool - Motley Fool - Mon Jul 07, 1:09PM CDT
When a company commercializes a building-block molecule with dozens, if not hundreds, of potential commercial uses, competition is bound to arrive sooner or later. When it comes to farnesene production, that competition may show up sooner than ...
What's the Value of Amyris' Molecule Development Strategy?
Maxx Chatsko, The Motley Fool - Motley Fool - Wed Jun 18, 11:50AM CDT
Artemisinin-based combination therapies are some of the most important weapons wielded by the developing world against malaria, which claims over 620,000 lives each year. While artemisinin is effective, its supply and cost is greatly affected by...
2014 Report on the International Synthetic Biology (Synthetic DNA, Synthetic Genes, Synthetic Cells, XNA, Chassis Organisms, DNA Synthesis, Oligonucleotide Synthesis) Market - Trends and Forecast to 2019
M2 - Wed Jun 18, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9bcz55/synthetic_biology) has announced the addition of the "2014 Report on the International Synthetic Biology (Synthetic DNA, Synthetic Genes, Synthetic Cells, XNA, Chassis Organisms, DNA Synthesis, Oligonucleotide Synthesis) Market - Trends and Forecast to 2019" report to their offering. Synthetic biology defined as the synthesis of artificial or natural components in order to form new artificial living system by re-molding existing biological elements. It aims to attain new preferred functions of artificially modified organisms intended for high yield production of biological systems. Synthetic biology plays an important role in the field of life sciences by developing cheap synthesis procedures. Increasing scientific research coupled with introduction of advanced technologies in synthetic biology will drive the growth of this market. The market for synthetic biology is segmented as: by products, by technologies and by applications. Product segment includes core products and enabling products. Core product segment comprises synthetic DNA, synthetic genes, synthetic cells, XNA and chassis organisms. While enabling products are segmented into DNA and oligonucleotide synthesis products. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Synthetic Biology Market, by Products Chapter 5 Global Synthetic Biology Market, by Technologies Chapter 6 Global Synthetic Biology Market, by Applications Chapter 7 Global Synthetic Biology Market, by Geography Chapter 8 Competitive Landscape Chapter 9 Recommendations Chapter 10 Company Profiles Companies Mentioned: - Agrivida, Inc. - Amyris, Inc. - Algenol Biofuels, Inc. - ATG:biosynthetics GmbH - Bayer AG - Bristol-Myers Squibb - BIONEER CORPORATION - Biosearch Technologies, Inc. - CBC Comprehensive Biomarker Center GmbH - Cobalt Technologies - DuPont, Inc. - Evolva SA - Exxon Mobil Corporation - Ginkgo Bioworks - GeneWorks Pty Ltd. - Genomatica, Inc. - GeneScript Corporation - Gevo, Inc. - Green Biologics Limited - New England Biolabs, Inc. - OriGene Technologies, Inc. - REG Life Sciences, LLC - Royal DSM - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/9b...ic_biology
Amyris Up 5.2%, Shares Break Through Resistance (AMRS)
Comtex SmarTrend(R) - Tue Jun 17, 11:39AM CDT
Amyris (NASDAQ:AMRS) is one of today's best performing low-priced stocks, up 5.2% to $3.85 on 1.2x average daily volume. Thus far today, Amyris has traded 326,000 shares, vs. average volume of 269,000 shares per day. The stock has outperformed the Dow (5.2% to the Dow's 0.1%) and outperformed the S&P 500 (5.2% to the S&P's 0.1%) during today's trading.
Total and Amyris Renewable Jet Fuel Ready for Use in Commercial Aviation
GlobeNewswire - Mon Jun 16, 6:55AM CDT
With the newly revised ASTM standard for jet fuel, Amyris (Nasdaq:AMRS) and Total (CAC:TOTF.PA) today begin to prepare to market a drop-in jet fuel that contains up to 10% blends of renewable farnesane.
A Warning for Biofuel Investors
Shamus Funk, The Motley Fool - Motley Fool - Thu Jun 12, 9:57AM CDT
It's hard to believe a company producing and selling shark liver oil and low-friction tire rubber could be telling a story that we've already heard before, but Amyris ' tale is one not unseen in the bio-product industry. Like a poorly written...
Takasago and Amyris to Begin Commercialization of Novel Fragrance Products
GlobeNewswire - Mon Jun 09, 6:12AM CDT
Takasago (TYO:4914), a global leader in the creation of flavors and fragrances for consumer products, and Amyris (Nasdaq:AMRS), a leading renewable products company, today announced the start of the next phase of their relationship to commercialize farnesene-derived fragrance molecules. Having successfully completed feasibility testing, Takasago agreed to move forward with commercialization, starting with a first purchase for scale-up this quarter.
The Good, the Bad, and the Ugly From Amyris' Financing Deal
Maxx Chatsko, The Motley Fool - Motley Fool - Wed May 28, 3:39PM CDT
Here's a list of words that were not uttered during the first-quarter conference call of synthetic biology leader Amyris on May 8: "Financing" "Convertible debt notes" "$90 million" Although it wasn't discussed on the call, the company...
Why Amyris Inc's Shares Jumped Today
Travis Hoium, The Motley Fool - Motley Fool - Fri May 23, 4:55PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Amyris Inc jumped 12% today after...
Amyris Prices $75 Million Convertible Senior Notes Due 2019
GlobeNewswire - Fri May 23, 6:00AM CDT
Amyris, Inc. (Nasdaq:AMRS) today announced that it has priced $75 million aggregate principal amount of 6.50% Convertible Senior Notes due 2019 (the "notes"
. The notes will be sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Amyris also granted the initial purchaser of the notes an option to purchase up to an additional $15 million aggregate principal amount of the notes. The sale is expected to close on May 29, 2014, subject to customary closing conditions. Why Amyris, Total SA, and The Boeing Company Are Excited About Renewable Jet Fuel
Maxx Chatsko, The Motley Fool - Motley Fool - Thu May 22, 8:42AM CDT
Boeing 777 aircraft (and more) around the world could soon be powered in part by renewable fuels. Source: United Airlines / Wikimedia Commons . The global aviation industry accounts for roughly 2% of all greenhouse gas emissions. On a per-passenger...
Amyris to Offer $75 Million Convertible Senior Notes Due 2019
GlobeNewswire - Thu May 22, 6:37AM CDT
Amyris, Inc. (Nasdaq:AMRS), a leading renewable chemicals and fuels company, today announced that it proposes to offer $75 million aggregate principal amount of Convertible Senior Notes due 2019 (the "notes"
, subject to market conditions and other factors. The notes are to be offered and sold in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Amyris also intends to grant to the initial purchaser of the notes an option to purchase up to an additional $15 million aggregate principal amount of notes. 4 Stocks Under $10 Making Big Moves
at The Street - Wed Apr 02, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
